{
    "hands_on_practices": [
        {
            "introduction": "The foundation of any genomic analysis is the quality of the raw sequencing data. The Phred quality score ($Q$) is a universally adopted metric that provides a logarithmic measure of the confidence in each base call. This exercise () will give you hands-on practice in translating these scores into concrete error probabilities and understanding their cumulative effect over large genomic regions, a critical first step in quality control.",
            "id": "5100154",
            "problem": "In a clinical laboratory setting for Pediatric Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES), base-level confidence is reported using the Phred quality score, which is defined in terms of the probability that a base call is incorrect. Consider a uniform region of length $10$ megabases, that is, $1.0 \\times 10^{7}$ bases. Suppose every base in this region is assigned a constant quality score $Q = 35$ by the sequencing instrument. Assume independent base-calling errors across positions.\n\nUsing the formal definition of the Phred quality score and standard probability theory for sums of independent Bernoulli trials, derive the per-base error probability $p_{\\mathrm{error}}$ and the expected number of incorrect base calls over the $10$ megabase region. Round both quantities to four significant figures. Express the expected number as a pure count (no units).",
            "solution": "The problem is validated as scientifically grounded, well-posed, and objective. It is based on standard definitions and principles in bioinformatics and probability theory.\n\nThe problem asks for two quantities: the per-base error probability, denoted as $p_{\\mathrm{error}}$, and the expected number of incorrect base calls in a genomic region of a specified length, given a constant Phred quality score.\n\nFirst, we address the per-base error probability, $p_{\\mathrm{error}}$. The Phred quality score, $Q$, is formally defined as a logarithmic measure of the error probability. The relationship is given by the equation:\n$$\nQ = -10 \\log_{10}(p_{\\mathrm{error}})\n$$\nwhere $p_{\\mathrm{error}}$ is the probability that the corresponding base call is incorrect.\n\nWe are given that the quality score is constant for all bases in the region, with a value of $Q = 35$. To find $p_{\\mathrm{error}}$, we must solve the defining equation for $p_{\\mathrm{error}}$.\nDividing both sides by $-10$, we have:\n$$\n-\\frac{Q}{10} = \\log_{10}(p_{\\mathrm{error}})\n$$\nTo isolate $p_{\\mathrm{error}}$, we use the property that if $y = \\log_{b}(x)$, then $x = b^{y}$. Applying this to our equation, we get:\n$$\np_{\\mathrm{error}} = 10^{-Q/10}\n$$\nSubstituting the given value $Q = 35$:\n$$\np_{\\mathrm{error}} = 10^{-35/10} = 10^{-3.5}\n$$\nTo express this as a numerical value, we can write $10^{-3.5}$ as $10^{0.5} \\times 10^{-4}$. Since $10^{0.5} = \\sqrt{10}$, we have:\n$$\np_{\\mathrm{error}} = \\sqrt{10} \\times 10^{-4} \\approx 3.16227766 \\times 10^{-4}\n$$\nRounding this to four significant figures, as requested, gives:\n$$\np_{\\mathrm{error}} \\approx 3.162 \\times 10^{-4}\n$$\n\nNext, we calculate the expected number of incorrect base calls over the entire region. The region has a length of $N = 10$ megabases, which is equivalent to $N = 1.0 \\times 10^{7}$ bases.\n\nThe process of calling each base can be modeled as a Bernoulli trial. Let $X_i$ be an indicator random variable for the $i$-th base in the sequence, where $i$ ranges from $1$ to $N$. We define $X_i = 1$ if the base call is incorrect and $X_i = 0$ if the base call is correct.\nThe probability of an incorrect call is $P(X_i = 1) = p_{\\mathrm{error}}$.\nThe probability of a correct call is $P(X_i = 0) = 1 - p_{\\mathrm{error}}$.\n\nThe expected value of a single Bernoulli trial is given by $E[X_i] = 1 \\cdot P(X_i = 1) + 0 \\cdot P(X_i = 0) = p_{\\mathrm{error}}$.\n\nThe total number of incorrect base calls, let's call it $K$, is the sum of these individual indicator variables over the entire region:\n$$\nK = \\sum_{i=1}^{N} X_i\n$$\nThe problem states that base-calling errors are independent. Due to the linearity of expectation, the expected value of a sum of random variables is the sum of their expected values, regardless of their independence.\n$$\nE[K] = E\\left[\\sum_{i=1}^{N} X_i\\right] = \\sum_{i=1}^{N} E[X_i]\n$$\nSince each base has the same constant quality score, the error probability $p_{\\mathrm{error}}$ is the same for all $N$ bases. Therefore, $E[X_i] = p_{\\mathrm{error}}$ for all $i$.\n$$\nE[K] = \\sum_{i=1}^{N} p_{\\mathrm{error}} = N \\cdot p_{\\mathrm{error}}\n$$\nThis result is also the mean of a binomial distribution, $B(N, p_{\\mathrm{error}})$, which precisely models the total number of errors in a sequence of $N$ independent trials.\n\nNow, we substitute the values for $N$ and $p_{\\mathrm{error}}$:\n$$\nN = 1.0 \\times 10^{7}\n$$\n$$\np_{\\mathrm{error}} = 10^{-3.5}\n$$\nThe expected number of incorrect calls is:\n$$\nE[K] = (1.0 \\times 10^{7}) \\times 10^{-3.5} = 10^{7} \\times 10^{-3.5} = 10^{7 - 3.5} = 10^{3.5}\n$$\nWe calculate the numerical value:\n$$\nE[K] = 10^{3.5} = \\sqrt{10} \\times 10^3 \\approx 3.16227766 \\times 1000 = 3162.27766\n$$\nRounding this value to four significant figures gives:\n$$\nE[K] \\approx 3162\n$$\n\nThe two requested quantities, rounded to four significant figures, are the per-base error probability $p_{\\mathrm{error}} \\approx 3.162 \\times 10^{-4}$ and the expected number of incorrect base calls $E[K] \\approx 3162$.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 3.162 \\times 10^{-4} & 3162 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "Identifying a genetic variant is only the beginning of the diagnostic journey; the true challenge lies in interpreting its clinical significance. The ACMG/AMP framework provides a systematic, evidence-based standard for this crucial task. In this practice (), you will step into the role of a clinical geneticist, synthesizing multiple lines of evidence—including inheritance patterns, population frequency, and functional data—to classify a variant and make a diagnostic conclusion.",
            "id": "5100142",
            "problem": "A $4$-year-old child presents with severe early-onset epileptic encephalopathy, global developmental delay, and hypotonia. Trio Whole Exome Sequencing (WES) identifies a heterozygous missense variant in a voltage-gated sodium channel gene with established haploinsufficiency disease mechanism for autosomal dominant pediatric epileptic encephalopathy. The variant is denoted $c.4021G>A$ ($p.Gly1341Arg$). The Genome Aggregation Database (gnomAD) reports this variant at an allele frequency of $1\\times 10^{-5}$ across aggregate populations, corresponding to a total allele count of $3$ out of approximately $300{,}000$ alleles surveyed. Parental testing and kinship analysis confirm the variant arose de novo in the proband (maternity and paternity confirmed). A well-established patch-clamp functional assay in a heterologous expression system, validated for this gene, demonstrates a $>90\\%$ reduction in peak current relative to wild-type channels, consistent with loss of function in a gene where loss of function is a known mechanism of disease for this phenotype.\n\nStarting from foundational principles in human genetics and population genetics (including the Central Dogma, genotype-to-phenotype causality, and Hardy–Weinberg equilibrium for interpreting rarity), and applying the American College of Medical Genetics and Genomics (ACMG) variant interpretation framework, select the most appropriate classification for this variant. Justify the specific evidence weights for de novo status, functional assay, and rarity in population datasets.\n\nWhich classification is most appropriate under ACMG rules, and why?\n\nA. Pathogenic\n\nB. Likely pathogenic\n\nC. Variant of uncertain significance\n\nD. Benign",
            "solution": "The user has provided a problem statement in clinical genetics that requires validation before proceeding to a solution.\n\n### Step 1: Extract Givens\n- **Patient Phenotype:** A $4$-year-old child with severe early-onset epileptic encephalopathy, global developmental delay, and hypotonia.\n- **Genetic Test:** Trio Whole Exome Sequencing (WES).\n- **Variant:** A heterozygous missense variant, denoted $c.4021G>A$ ($p.Gly1341Arg$), in a voltage-gated sodium channel gene.\n- **Inheritance Pattern:** The variant arose de novo in the proband, with confirmed maternity and paternity.\n- **Gene-Disease Mechanism:** The gene has an established haploinsufficiency mechanism for autosomal dominant pediatric epileptic encephalopathy. This means that loss of function (LoF) in one of the two gene copies is a known cause of the disease.\n- **Population Frequency Data:** The variant is reported in the Genome Aggregation Database (gnomAD) with an allele frequency of $1 \\times 10^{-5}$ (total allele count of $3$ out of approximately $300,000$ alleles).\n- **Functional Data:** A well-established patch-clamp functional assay demonstrates a reduction in peak current greater than $90\\%$ relative to wild-type, which is consistent with loss of function.\n- **Task:** Classify the variant using the American College of Medical Genetics and Genomics (ACMG) framework and justify the evidence weights.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is critically evaluated for validity.\n\n- **Scientifically Grounded:** The problem is firmly grounded in the principles of human genetics, molecular biology, and clinical diagnostics. Trio WES, de novo mutations, haploinsufficiency, voltage-gated sodium channelopathies, patch-clamp electrophysiology, population genetics databases (gnomAD), and the ACMG/AMP variant interpretation framework are all standard, well-established concepts and methodologies in the field. The scenario is scientifically realistic and coherent.\n- **Well-Posed:** The problem provides a comprehensive set of data points (phenotype, inheritance, population frequency, functional evidence) and asks for the application of a specific, standardized rule set (ACMG/AMP guidelines) to reach a conclusion. The question is unambiguous and all necessary information to derive a unique answer is provided.\n- **Objective:** The information is presented as objective clinical and laboratory findings. There are no subjective or opinion-based statements.\n\nThe problem statement successfully passes validation as it is scientifically sound, well-posed, objective, and contains a complete and consistent set of information required for its resolution. There are no identifiable flaws.\n\n### Step 3: Derivation of Solution\nThe solution is derived by applying the 2015 ACMG/AMP \"Standards and Guidelines for the Interpretation of Sequence Variants\". This framework uses evidence codes of varying strengths (Very Strong, Strong, Moderate, Supporting) to classify variants into one of five categories: Pathogenic, Likely Pathogenic, Variant of Uncertain Significance, Likely Benign, or Benign.\n\nThe foundational principles are as follows:\n1.  **Central Dogma and Genotype-to-Phenotype Causality:** A change in the DNA sequence (genotype, e.g., $c.4021G>A$) can lead to an altered protein (e.g., $p.Gly1341Arg$), which in turn may disrupt its biological function (e.g., reduced ion channel current), causing a specific disease (phenotype, e.g., epileptic encephalopathy).\n2.  **Population Genetics (Hardy–Weinberg Equilibrium Context):** For severe, dominantly inherited diseases that manifest early in life and reduce reproductive fitness, natural selection will act to keep the causative alleles at an extremely low frequency in the general population. Therefore, the rarity of a variant is a necessary, albeit not sufficient, condition for it to be pathogenic for such a disorder.\n\nWe will now systematically evaluate the provided evidence against the ACMG/AMP criteria.\n\n1.  **De Novo Status (PS2 - Pathogenic Strong):** The problem states, \"Parental testing and kinship analysis confirm the variant arose de novo in the proband (maternity and paternity confirmed).\" The appearance of a variant in an affected individual that is absent from both biologically confirmed parents is very strong evidence of causality for a dominant disorder. This meets the criterion **PS2**, which is weighted as **Strong** evidence for pathogenicity.\n\n2.  **Functional Studies (PS3 - Pathogenic Strong):** The problem describes, \"A well-established patch-clamp functional assay...demonstrates a $>90\\%$ reduction in peak current relative to wild-type channels\". This result is \"consistent with loss of function in a gene where loss of function is a known mechanism of disease for this phenotype.\" A well-validated functional study showing a clear damaging effect that aligns with the known disease mechanism is powerful evidence. This meets criterion **PS3**, which is also weighted as **Strong** evidence for pathogenicity.\n\n3.  **Allele Frequency (PM2 - Pathogenic Moderate):** The variant is present in gnomAD at an allele frequency of $1 \\times 10^{-5}$. For a severe, childhood-onset autosomal dominant disease like the one described, causative variants are expected to be extremely rare. An allele frequency of $1 \\times 10^{-5}$ is well below the threshold of what would be considered too common for such a disorder. The absence of a variant from, or its presence at an extremely low frequency in, large population databases is moderate evidence for pathogenicity. This meets criterion **PM2**, weighted as **Moderate**.\n\n4.  **Phenotype Specificity (PP4 - Pathogenic Supporting):** The patient's phenotype (\"severe early-onset epileptic encephalopathy, global developmental delay, and hypotonia\") is highly consistent with diseases caused by variants in voltage-gated sodium channel genes. While epileptic encephalopathy is genetically heterogeneous, the overall clinical picture combined with the specific gene class makes the phenotype strongly suggestive. This can be considered to meet criterion **PP4**, weighted as **Supporting**.\n\n**Combining the Evidence:**\nAccording to the ACMG/AMP combinatorial rules, the classification is determined by the set of criteria met. We have accumulated:\n- **PS2** (Strong)\n- **PS3** (Strong)\n- **PM2** (Moderate)\n- **PP4** (Supporting)\n\nThe rule for a **Pathogenic** classification states that a variant can be classified as such if it meets criteria such as:\n- $\\geq 2$ Strong (e.g., PS1-PS4)\n\nIn this case, we have identified two Strong criteria: **PS2** and **PS3**. This combination alone is sufficient to classify the variant as Pathogenic. The additional Moderate (PM2) and Supporting (PP4) evidence further strengthen this conclusion but are not strictly necessary to reach the \"Pathogenic\" threshold.\n\nTherefore, the most appropriate classification for the $c.4021G>A$ ($p.Gly1341Arg$) variant is Pathogenic.\n\n### Option-by-Option Analysis\n\n**A. Pathogenic**\nThis classification requires meeting a high evidence threshold, such as having at least two \"Strong\" pieces of pathogenic evidence. As derived above, the confirmed de novo status (PS2) and the conclusive loss-of-function result from a well-established functional assay (PS3) provide the necessary two \"Strong\" criteria. Therefore, this classification is appropriate.\n**Verdict: Correct.**\n\n**B. Likely pathogenic**\nThis classification is used when the evidence is strong but falls short of the \"Pathogenic\" threshold (e.g., 1 Strong and 1-2 Moderate criteria). The evidence in this case (2 Strong criteria) exceeds the requirements for \"Likely pathogenic\" and fully supports a \"Pathogenic\" classification. While a pathogenic variant is, by definition, also likely pathogenic, the ACMG framework directs the user to apply the most definitive classification supported by the evidence.\n**Verdict: Incorrect.**\n\n**C. Variant of uncertain significance**\nThis classification is reserved for cases where there is insufficient evidence for a more definitive classification, or where the evidence is conflicting. Here, multiple, independent lines of evidence (inheritance, population frequency, functional data, phenotype) are all consistent and point unequivocally towards pathogenicity.\n**Verdict: Incorrect.**\n\n**D. Benign**\nThis classification is used for variants that are common in the general population or have been functionally shown to have no impact. The variant in question is extremely rare and has been functionally demonstrated to cause a severe loss of function, which is the exact opposite of what would be expected for a benign variant.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Beyond the technical and clinical aspects of individual cases, the implementation of genomic technologies involves critical decisions at the health system level. Cost-effectiveness analysis provides a rational framework for comparing different diagnostic strategies, balancing their costs against their benefits. This exercise () challenges you to calculate and interpret the Incremental Cost-Effectiveness Ratio (ICER), a key metric used to determine whether the added diagnostic yield of a more expensive test like WGS justifies its higher cost compared to WES.",
            "id": "5100105",
            "problem": "A pediatric genetics clinic is evaluating two next-generation sequencing (NGS) modalities for children with undiagnosed suspected Mendelian disorders: Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS). In this context, consider the following foundational principles: the Central Dogma of Molecular Biology establishes that DNA variation can cause altered RNA and protein function, which underlies Mendelian disease; Whole Exome Sequencing (WES) targets protein-coding exons, while Whole Genome Sequencing (WGS) interrogates the entire genome, including noncoding regulatory regions. For a given patient, the diagnostic yield is the probability that the test identifies a pathogenic variant sufficient to establish a molecular diagnosis. Let the expected diagnostic yield per patient be denoted by $p$ and the expected cost per patient be denoted by $C$. The incremental cost-effectiveness ratio (ICER) for WGS versus WES is defined as the ratio of the increment in expected cost to the increment in expected diagnostic yield.\n\nYou are given that the expected cost for WES is $C_{\\text{WES}} = 1200$ United States dollars (USD) and the expected diagnostic yield per patient is $p_{\\text{WES}} = 0.30$. For WGS, the expected cost is $C_{\\text{WGS}} = 2000$ USD and the expected diagnostic yield per patient is $p_{\\text{WGS}} = 0.42$. Starting from the core definitions of expected value and incremental analysis, derive the expression for the ICER per additional diagnosis and compute its value using the provided data. Round your numeric result to four significant figures and express the final ICER in United States dollars (USD).\n\nAfter computing the ICER, briefly state the decision criterion in words: given a willingness-to-pay threshold per additional diagnosis denoted by $W$, under what condition is WGS considered cost-effective compared with WES?",
            "solution": "The problem requires the derivation and calculation of the Incremental Cost-Effectiveness Ratio (ICER) for Whole Genome Sequencing (WGS) relative to Whole Exome Sequencing (WES), followed by a statement of the decision criterion for cost-effectiveness.\n\nFirst, we establish the formal definitions and given values.\nLet $C_{\\text{WES}}$ and $p_{\\text{WES}}$ denote the expected cost per patient and the diagnostic yield per patient for WES, respectively.\nLet $C_{\\text{WGS}}$ and $p_{\\text{WGS}}$ denote the expected cost per patient and the diagnostic yield per patient for WGS, respectively.\n\nThe provided data are:\n-   Cost for WES: $C_{\\text{WES}} = 1200$ United States dollars (USD)\n-   Diagnostic yield for WES: $p_{\\text{WES}} = 0.30$\n-   Cost for WGS: $C_{\\text{WGS}} = 2000$ USD\n-   Diagnostic yield for WGS: $p_{\\text{WGS}} = 0.42$\n\nThe ICER is defined as the ratio of the increment in expected cost to the increment in expected diagnostic yield, when comparing a new intervention (WGS) to a baseline or standard intervention (WES).\n\nThe increment in expected cost, $\\Delta C$, is the difference between the cost of WGS and the cost of WES:\n$$\n\\Delta C = C_{\\text{WGS}} - C_{\\text{WES}}\n$$\nThe increment in expected diagnostic yield, $\\Delta p$, is the difference between the yield of WGS and the yield of WES:\n$$\n\\Delta p = p_{\\text{WGS}} - p_{\\text{WES}}\n$$\nThe diagnostic yield, $p$, is the probability of achieving a diagnosis for a single patient. Consequently, $\\Delta p$ represents the additional probability of diagnosis when using WGS over WES. An interpretation is that if we test a large number of patients, $\\Delta p$ is the fraction of additional patients who will receive a diagnosis. The ICER thus represents the cost per additional diagnosis.\n\nThe expression for the ICER is:\n$$\n\\text{ICER} = \\frac{\\Delta C}{\\Delta p} = \\frac{C_{\\text{WGS}} - C_{\\text{WES}}}{p_{\\text{WGS}} - p_{\\text{WES}}}\n$$\nWe now substitute the given numerical values into this expression.\n\nThe increment in cost is:\n$$\n\\Delta C = \\$2000 - \\$1200 = \\$800\n$$\nThe increment in diagnostic yield is:\n$$\n\\Delta p = 0.42 - 0.30 = 0.12\n$$\nThis increment of $0.12$ implies that for every $100$ patients tested with WGS instead of WES, an additional $12$ patients are expected to receive a definitive molecular diagnosis.\n\nNow, we compute the value of the ICER:\n$$\n\\text{ICER} = \\frac{\\$800}{0.12}\n$$\nThe calculation proceeds as follows:\n$$\n\\text{ICER} = \\frac{800}{12 \\div 100} = \\frac{800 \\times 100}{12} = \\frac{80000}{12} = \\frac{20000}{3}\n$$\nConverting this fraction to a decimal gives:\n$$\n\\text{ICER} = 6666.666... \\text{ USD per additional diagnosis}\n$$\nThe problem requires the result to be rounded to four significant figures. The first four digits are $6666$, and the fifth digit is $6$, so we round up the fourth digit.\n$$\n\\text{ICER} \\approx 6667 \\text{ USD per additional diagnosis}\n$$\nThe final part of the problem asks for the decision criterion in words, using a willingness-to-pay (WTP) threshold, $W$. The threshold $W$ represents the maximum amount that a healthcare payer or society is willing to pay for one additional unit of a desired health outcome, which in this context is one additional diagnosis. An intervention is considered cost-effective if its ICER is less than or equal to this threshold.\n\nTherefore, the decision criterion is: WGS is considered cost-effective compared with WES if the incremental cost per additional diagnosis is less than or equal to the willingness-to-pay threshold. Formally, this is expressed as:\n$$\n\\text{ICER} \\le W\n$$",
            "answer": "$$\n\\boxed{6667}\n$$"
        }
    ]
}